Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

15
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence...
15
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

15
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor,...
15
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

23
Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
23
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

18
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH...
18
Goiter01:27

Goiter

24
Goiter refers to an abnormal enlargement of the thyroid gland that may appear as a diffuse goiter (uniform enlargement) or nodular (single or multiple nodules). Functionally, it is classified as nontoxic (normal/low hormone levels) or toxic (excess hormone production).PathophysiologyDiffuse thyroid enlargement typically results from prolonged stimulation by thyroid-stimulating hormone (TSH) or TSH-like agents, commonly seen in hypothyroidism or iodine deficiency. In contrast, in hyperthyroid...
24
Autoimmune Disorders01:29

Autoimmune Disorders

2.3K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fibrous Dysplasia in Hospitalized Patients in France: Prevalence and Associated Manifestations from a Health Database.

The Journal of clinical endocrinology and metabolism·2026
Same author

Genomic newborn screening as a paradigm shift in rare disease management, with emphasis on endocrine conditions.

Annales d'endocrinologie·2026
Same author

Genomic newborn screening as a paradigm shift in rare disease management, with emphasis on endocrine conditions.

Annales d'endocrinologie·2026
Same author

Comparison of traditional and new treatments for fibrous dysplasia: a systematic review and meta-analysis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Reply to the letter by Dr Karlsson 'Rationale behind the European Thyroid Association 2024 Guideline to treat the Allan-Herndon-Dudley syndrome with tiratricol?'

European thyroid journal·2025
Same author

Prospective Multicenter Evaluation of [<sup>11</sup>C]Methionine PET/MRI Sensitivity Compared with MRI for Localizing Small Pituitary Neuroendocrine Tumor or Pituitary Adenoma in Cushing Disease.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2025
Same journal

[Prolonged fever].

La Revue du praticien·2026
Same journal

[Lower gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[A history of child abuse intervention in the West].

La Revue du praticien·2026
Same journal

[Agranulocytose médicamenteuse].

La Revue du praticien·2026
Same journal

[Patient education in heart failure].

La Revue du praticien·2026
See all related articles

Related Experiment Video

Updated: Apr 26, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

2.8K

[Graves' disease].

Frédéric Illouz, Patrice Rodien

    La Revue Du Praticien
    |August 6, 2014
    PubMed
    Summary
    This summary is machine-generated.

    Graves' disease causes remain unclear, impacting diagnosis and treatment. Research aims to identify predictive markers for relapse and improve management, especially during pregnancy.

    More Related Videos

    Author Spotlight: Integrating Ultrasound Imaging with Biochemical Markers for Thyroid Disease Diagnosis
    05:41

    Author Spotlight: Integrating Ultrasound Imaging with Biochemical Markers for Thyroid Disease Diagnosis

    Published on: February 9, 2024

    1.3K
    Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
    10:27

    Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

    Published on: December 15, 2011

    23.9K

    Related Experiment Videos

    Last Updated: Apr 26, 2026

    Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
    04:39

    Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

    Published on: March 17, 2023

    2.8K
    Author Spotlight: Integrating Ultrasound Imaging with Biochemical Markers for Thyroid Disease Diagnosis
    05:41

    Author Spotlight: Integrating Ultrasound Imaging with Biochemical Markers for Thyroid Disease Diagnosis

    Published on: February 9, 2024

    1.3K
    Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
    10:27

    Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

    Published on: December 15, 2011

    23.9K

    Area of Science:

    • Endocrinology
    • Immunology

    Context:

    • Graves' disease pathogenesis, particularly the role of TSH receptor antibodies, requires further elucidation.
    • Current treatments for Graves' disease lack definitive superiority, necessitating exploration of predictive relapse markers.

    Purpose:

    • To review the current understanding of Graves' disease etiology and diagnosis.
    • To discuss established and emerging therapeutic strategies for Graves' disease and its complications.
    • To highlight the complexities of managing Graves' disease during pregnancy.

    Summary:

    • The genetic and environmental factors contributing to Graves' disease and TSH receptor antibody development are not fully understood.
    • Antithyroid drugs are standard treatment, but predicting relapse for timely surgical or radiometabolic intervention is challenging.
    • Graves' orbitopathy management involves severity assessment, with IV steroids for active cases and ongoing evaluation of new therapies.
    • Pregnancy with Graves' disease demands a multidisciplinary approach, fetal monitoring, and cautious drug selection due to teratogenicity concerns, favoring propylthiouracil in early stages.

    Impact:

    • Improved understanding may lead to earlier diagnosis and more personalized treatment strategies for Graves' disease.
    • Development of predictive markers could optimize the use of surgical or radiometabolic treatments.
    • Enhanced management protocols for Graves' orbitopathy and pregnancy-related cases will improve patient outcomes.